Diallyl disulfide prevention of Cis-diammine dichloroplatinum-induced nephrotoxicity and leukopenia in rats: Potential adjuvant effects

Nutrition and Cancer

Volumn 60, Issue 6, 2008, Pages 784-791

  Chiarandini Fiore, Jessica P ^a   Fanelli, Silvia L ^a   De Ferreyra, Elida C ^a   Castro, Jose A ^a,b  

^a Centro de Investigaciones Toxicologicos   (Argentina)

^b Instituto de Investigaciones Cientificas y Tecnicas de Las Fuerzas Armadas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; DIALLYL DISULFIDE; HYDROGEN PEROXIDE; IRON; PLATINUM; REACTIVE OXYGEN METABOLITE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED DISEASE; HISTOPATHOLOGY; KIDNEY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NEPHROTOXICITY; NONHUMAN; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; UREA BLOOD LEVEL;

ALLYL COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMILUMINESCENT MEASUREMENTS; CISPLATIN; CREATININE; DISULFIDES; KIDNEY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TERT-BUTYLHYDROPEROXIDE;

ANIMALIA; RATTUS;

EID: 56249092774     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802100869     Document Type: Article

References (38)

1. LebWohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34, 1522-1534, 1998.
2. Wong E and Giandomenico CM: Current status of platinum-based antitumor drugs. Chem Rev 99, 2451-2466, 1999.
3. Jakupec MA, Galanski M, and Keppler, BK: Tumor-inhibiting platinum complexes: state of the art and future perspectives. Rev Physiol Biochem Pharmacol 146, 1-54, 2003.
4. Ferguson LR and Pearson AE: The clinical use of mutagenic anticancer drugs. Mutat Res 355, 1-12, 1996.
5. O'Dwyer PJ, Stevenson JP, and Johnson SW: Clinical Status of cisplatin, carboplatin and other platinum-based antitumor drugs. In: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Lippert B (ed.). Verlag Helvetica Chimica Acta, Zürich, Switzerland, Wiley-VCH. 1999, pp. 31-69.
6. Arany I and Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 23, 460-464, 2003.
7. Taguchi T, Nazneen A, Abid MR, and Razzaque MS: Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol 148, 107-121, 2005.
8. Srivastava RC, Farookh A, Ahmad N, Misra M, Hasan SK, et al.: Reduction of Cis-Platinum induced nephrotoxicity by zinc histidine complex: the possible implication of nitric oxide. Biochem Mol Biol Int 36, 855-862, 1995.
9. Matsushima H, Yonemura K, Ohishi K, and Hishida A: The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 131, 518-526, 1998.
10. Sadzuka Y, Shoji T, and Takino Y: Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 43, 1873-1875, 1992.
11. Baliga R, Zhang Z, Baliga M, Ueda N, and Shah SV: In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53, 394-401, 1998.
12. Khynriam D and Prasad SB: Changes in glutathione related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol Toxicol 18, 349-358, 2002.
13. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, et al.: Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 142, 178-186, 2003.
14. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, et al.: Effects of hydroxil radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73, 1499-1510, 2007.
15. Reed E: Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon? Curr Opin Oncol 3, 1055-1059, 1991.
16. Lawley PD and Philips DH: DNA adducts from chemotherapeutic agents. Mutat Res 355, 13-40, 1996.
17. Block E: The organosulfur chemistry of the Genus Allium - implications for the organic chemistry of sulfur. Angew Chem Int Ed Engl 31, 1135-1178, 1992.
18. Dausch J and Nixon W. Garlic: a review of its relationship to malignant disease. Prev Med 19, 346-361, 1990.
19. Guyonet D, Belloir C, Suschetet M, Siess MH, and Le Bon AM: Antimutagenic activity of organosulfur compounds from Allium is associated with phase II enzyme induction. Mutat Res 495, 135-145, 2001.
20. Stegemann H and Loeschcke V: Microdetermination of nitrogen as indophenol blue by cloramine-T oxidation. Hoppe-Seyler's Z Physiol Chem 329, 241-248, 1962.
21. Butler AR: The Jaffé reaction: identification of the coloured species. Clin Chem Acta 59, 227-232, 1975.
22. Basinger MA, Jones MM, and Holscher MA: L-methionine suppress pathological sequelae of cis-platinum in the rat. Fundam Appl Toxicol 14, 568-577, 1990.
23. Boveris A, Fraga CG, Varsavsky AI, and Koch OR: Increased chemiluminescence and superoxide production in liver of chronically ethanol treated rats. Arch Biochem Biophys 227, 534-541, 1983.
24. Castro GD, Costantini MH, Delgado de Layño AM, and Castro JA: Rat liver microsomal and nuclear activation of methanol to hydroxymethyl free radicals. Toxicol Lett 129, 227-236, 2002.
25. Lowry OH, Rosebrough NJ, Farr AL, and Randall, RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275, 1951.
26. Gad SC: Statistics for toxicologists. In: Principles and Methods of Toxicology, Hayes AW (ed.). 4th ed. Philadelphia: Taylor & Francis, 2001, pp. 285-364.
27. Ali BH and Al Moundhri MS: Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44, 1173-1183, 2006.
28. Kosmider B and Osiecka R: Flavonoid compounds: a review of anticancer properties and interactions with cis-diamminedichloroplatinum (II). Drug Dev Res 63, 200-211, 2004.
29. Fanelli SL, Castro GD, Toranzo EGD, and Castro JA: Mechanisms of the preventive properties of garlic components in the carbon tetrachloride-promoted oxidative stress: diallyl sulfide, diallyl disulfide, allyl mercaptan and allylmethyl sulfide. Res Commun Mol Pathol Pharmacol 102, 163-174, 1998.
30. Dwivedi C, John LM, Schimidt DS, and Engineer FN: Effect of oil-soluble organosulfur compounds from garlic on doxorubicin-induced lipid peroxidation. Anticancer Drugs 9, 291-294, 1998.
31. Siess MH, Le Bon AM, Canivenc-Lavier MC, and Suschetet M: Modification of hepatic drug metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 120, 195-201, 1997.
32. Shimada M, Liu L, Nussler N, Jonas S, Langrehr JM, et al.: Human hepatocytes are protected from ethanol-induced cytotoxicity by DADS via cyP2E1 inhibition. Toxicol Lett 163, 242-249, 2006.
33. Knowles LM and Milner JA: Possible mechanism by which allyl sulfides suppress neoplastic cell proliferation. J Nutr 131, 1061S-1066S, 2001.
34. Herman-Antosiewicz A and Shivendra SV: Signal transduction pathway leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organ sulfur compounds: a review. Mutat Res 555, 121-131, 2004.
35. Wu XJ, Kassie F, and Mersch-Sundermann V: Induction of apoptosis in tumor cells by naturally occurring sulfur-containing compounds. Mutat Res 589, 81-102, 2005.
36. Arunkumar A, Vijayababu MR, Venkataraman P, Senthilkumar K, and Arunakaran J: Chemoprevention of rat prostate carcinogenesis by diallyl disulfide, an organsulfur compound of garlic. Biol Pharm Bull 29, 375-379, 2006.
37. Yellin SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C, et al.: Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 85, 223-232, 1994.
38. Kameyama Y and Gemba M: The iron chelator deferoxamine prevents cisplatin-induced lipid peroxidation in rat kidney cortical slices. Jpn J Pharmacol 57, 259-262, 1991.